Abstract
Embelin, a small molecule quinone with a co-clinical power for castrate-resistant prostate cancer.
Highlights
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer by Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al (2013)
“Prevention is better than cure” we look forward for tailoring new treatment paradigms for the prevention of castration-resistant prostate cancers (CRPC)
Lunardi and team from Beth Israel Deaconess Medical Center, Harvard Medical School and other institutes unveiled how a co-clinical strategy comprising of a naturally occurring hydroxybenzoquinone, Embelin which is a small molecule X-linked inhibitor of apoptosis (XIAP), in dual/triple combinations with MDV3100 an androgen receptor (AR) antagonist, Bicalutamide an antiandrogen (Casodex) or Dutasteride a SRD5A1 inhibitor and Androgendeprivation therapy (ADT) currently in clinical trials are the targets for CRPC (Lunardi et al, 2013)
Summary
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer by Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al (2013). Hormonal therapies help in controlling advanced prostate cancers for some time and later on fail to respond, evolve resistance mechanisms, and undergo genetic deregulations with poor patient survival rate and no cure.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
